Drug Database
ME

meningococcal meningitis conjugate vaccine (Manhaixin / Menhycia)

✓ Approved

CanSino Biologics · 细胞治疗 · 细胞治疗

什么是 meningococcal meningitis conjugate vaccine?

meningococcal meningitis conjugate vaccine 是一种细胞治疗,由CanSino Biologics研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名Manhaixin, Menhycia
公司CanSino Biologics
药物类别细胞治疗, 疫苗
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

治疗适应症

meningococcal meningitis conjugate vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsMeningococcal bacteraemia✓ Approved

相关研究文献

PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-17

Alginate-DNA Core-Shell Hydrogel Microspheres Program Antigen Release Kinetics for Potent Single-Dose Subunit Vaccination.

Shen Fengyun F, Yan Lingling L, Sun He H, Wu Junjie J et al.

Conventional vaccine sustained release strategies exhibit monophasic antigen kinetics that fail to align with the temporal order of T and B cell activation, limiting single-dose efficacy. Using a protein-carrier peptide vaccine model, we designed an alginate-DNA core-shell hydrogel microsphere that programmed differential antigen release kinetics through orthogonal loading mechanisms. Physical encapsulation enabled carrier protein release within 3 days to prime T cells, while DNA cross-linking sustained epitope-carrier protein conjugate release over 11 days to drive B cell responses, achieving a release interval exceeding 8 days that orchestrates sequential T and B cell activation. In a single immunization, this strategy induces significantly higher epitope-specific IgG titers compared to formulations with either co-rapid or co-sustained release. A SARS-CoV-2 peptide vaccine based on our strategy elicits substantially stronger humoral immunity than traditional aluminum-adjuvanted vaccines. This work establishes orthogonal loading-mediated kinetic programming as a versatile platform for next-generation single-injection subunit vaccines.

PMID 43042745
阅读全文 →
PubMedGeriatrie et psychologie neuropsychiatrie du vieillissement2026-11-17

[2026 vaccination schedule for adults aged 65 years and older: towards comprehensive vaccine-based prevention in older age].

Corroyer-Simovic Bénédicte B

The 2026 French vaccination schedule redefines geriatric prevention, extending its focus beyond the prevention of infectious diseases to the preservation of independence and functional health. Yet vaccination coverage in France remains inadequate. To address immunosenescence, the strategy prioritizes comprehensive protection against respiratory infections caused by influenza viruses, SARS-CoV-2, pneumococcus and respiratory syncytial virus (RSV). For influenza, guidelines recommend the preferential use of enhanced vaccines-either high-dose or adjuvanted formulations-to improve protection in older adults and reduce hospital admissions. Covid-19 boosters remain essential for this vulnerable population, with the adjuvanted recombinant protein vaccine Nuvaxovid® available alongside mRNA vaccines. Pneumococcal prevention is considerably simplified: a single dose of the 21-valent pneumococcal conjugate vaccine (PCV21, Capvaxive®) is recommended for all adults aged 65 years and older. This vaccine covers the serotypes responsible for 83.5% of invasive pneumococcal disease cases in France in 2024. RSV vaccination is indicated for adults aged 75 years and older and for those aged 65 years and older with cardiopulmonary comorbidities, providing protection against severe disease and reducing hospital admissions during winter. Beyond respiratory infections, vaccination against herpes zoster with the adjuvanted recombinant vaccine Shingrix® is recommended for all adults aged 65 years and older. Recent data associate this vaccination not only with the prevention of postherpetic neuralgia but also with a reduced risk of stroke. Tdap-IPV boosters remain essential in the context of recent pertussis epidemics and the persistent risk of tetanus in older adults. Vaccine coadministration is safe and should be offered to improve coverage and reduce the number of visits required. When vaccination records are unavailable, the priority is to proceed with vaccination rather than delay protection. This proactive, integrated approach aims to address inadequate vaccination coverage, reduce mortality and preserve independence in older adults.

PMID 43042679
阅读全文 →
PubMedJournal of clinical immunology2026-11-17

SIMPATHY Study: Specific Antibody Response to Typhim Vi Polysaccharide as a Surrogate Marker of Infectious Risk in Secondary Immunodeficiency Associated with B Cell Cancer.

Peixoto-Rodriguez Alejandro A, Melero Josefa J, de Andrés Ana A, López-Granados Eduardo E et al.

Recurrent and severe infections represent a major cause of morbidity and mortality of secondary immunodeficiency (SID) associated with B-cell lymphoproliferative syndromes (B-CLPD). Nevertheless, immunological evaluation and prophylactic interventions are often delayed until infectious complications occur. Early vaccination is therefore relevant not only because it provides protection during the initial phases of B-CLPD, but also because it enables the identification of patients at higher risk of infection. In this context, assessment of antigen-specific humoral response has been proposed as a useful biomarker for identifying patients with greater clinical vulnerability. We conducted SIMPATHY (Secondary Immunodeficiency Multicentric study on the Antibody Production to Typhi vaccine), a multicentre, retrospective, observational study including 128 individuals with B-CLPD, classified according to the presence or absence of severe and/or recurrent infections, as well as healthy controls. Specific IgG antibody responses to Streptococcus pneumoniae (13-valent conjugate, Prevenar), Salmonella typhi (Typhim Vi), and tetanus toxoid vaccines were assessed at baseline and 4-weeks after vaccination. Among 128 individuals analysed, patients with B-CLPD showed significant immunological and clinical differences compared to healthy controls, particularly in vaccine-specific antibody responses and lymphocyte subsets. B-CLPD patients with recurrent or severe infections exhibited markedly reduced pre-vaccination anti-pneumococcal (p = 0.03) and post-vaccination anti-pneumococcal (p = 0.001) and anti-Salmonella typhi Vi titers (p = 0.1), highlighting impaired vaccine-specific antibody responses as potential predictors of infection risk. An immunological classification identified two subgroups within B-CLPD, predominant antibody defect and combined immune defect, with a trend toward higher respiratory infection rates in the latter, suggesting broader immune dysfunction.

PMID 43040101
阅读全文 →
PubMedNorthern clinics of Istanbul2026-11-17

Questioning causal attribution between ozone therapy, pneumocephalus, and meningitis: A critical appraisal of the case report by Elmas Dal.

Franzini Marianno M, Vaiano Francesco F, Tirelli Umberto U, Ricevuti Giovanni G et al.

PMID 43041726
阅读全文 →
PubMedNature communications2026-11-17

Molecular architecture of Cryptococcus cell walls reveals species-specific chitosan-dependent remodeling.

Ankur Ankur A, Upadhya Rajendra R, Doosti Mahsa M, Ferreira Davis D et al.

Cryptococcus neoformans and Cryptococcus gattii are fungal pathogens that cause life-threatening infections, including cryptococcal meningitis. A distinctive feature of the cryptococcal cell wall is the extensive deacetylation of chitin to chitosan, a modification that is essential for virulence but whose structural role in cell-wall organization remains poorly understood. Here, we analyze the cell walls of wild-type strains of both species and their avirulent chitosan-deficient mutants, which serve as vaccine candidates. Loss of chitosan disrupted cell morphology and altered cell-wall ultrastructure, with more pronounced defects in C. neoformans. Solid-state NMR reveals that aggregated α-(1→3)-glucans form the principal rigid domain of the cell wall in both species and are closely associated with chitin microfibrils, whereas surrounding β-glucans and mannoproteins constitute a more dynamic matrix. Chitosan modulates hydration and flexibility, and its loss increases chitin exposure and triggers species-specific remodeling of the polysaccharide network. In C. neoformans, chitosan depletion increased α-(1→3)-glucan content and reduced β-glucan levels, whereas C. gattii selectively lost one α-(1→3)-glucan subtype while maintaining β-glucan levels. Although capsule production remained intact, chitosan deficiency altered glucuronoxylomannan linkage patterns and mannoprotein composition. These findings reveal how chitosan organizes cryptococcal cell-wall architecture and highlight distinct structural adaptation strategies among pathogenic Cryptococcus species.

PMID 43039940
阅读全文 →
PubMedExpert review of vaccines2026-11-17

Evaluating the potential health and economic impact of different vaccination strategies with the adult-specific 21-valent pneumococcal conjugate vaccine in adults aged ≥ 65 years in Japan.

Mueller Peter P PP, Tajima Atsushi A, Cassell Kelsie K, Matsuki Taizo T et al.

We estimated the health and economic impact of adult pneumococcal vaccination strategies in Japan, comparing the adult-specific PCV21 (aPCV21) to PCV20. A published Markov model simulated the epidemiology of pneumococcal disease in Japanese adults aged ≥ 65 years over a lifetime horizon using single- and multi-cohort analyses. Outcomes included cases of invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), disease-related deaths, and direct and indirect costs (2023 Japanese yen [¥]). The base case evaluated vaccination at age 65, while scenario analyses assessed expanded age-based (≥65) vaccination, coverage rates, duration of protection, and indirect protection. Compared to PCV20, aPCV21 prevented 35% more IPD outcomes (cases and deaths) and 33% more NBPP outcomes in the base case. Combined direct and indirect disease/death-related cost savings versus no vaccination increased from ¥3,983 million with PCV20 to ¥5,299 million with aPCV21. Expanding age-based vaccination from adults aged 65 to ≥65 years, prevented an additional 12% points of IPD outcomes and 6% points of NBPP outcomes. Across all scenario analyses, aPCV21 prevented ≥ 25% more cases and costs compared to PCV20. Based on scenario analyses, the use of aPCV21 in Japanese adults provides substantial health and economic benefits compared to PCV20.

PMID 43040205
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多meningococcal meningitis conjugate vaccine